

September 23, 2016

To,
National Stock Exchange of India Ltd.
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra East,
Mumbai-400051

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400023

Scrip Code: JUBILANT

Scrip Code: 530019

Dear Sir/Madam,

Sub: Proposal to issue unsecured high yield bonds by our wholly-owned subsidiary Jubilant Pharma Limited (a company incorporated under the laws of Singapore), outside India, under Regulation S of the U.S. Securities Act of 1933, as amended (the “US Securities Act”).

Pursuant to Regulation 30(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), which requires a listed entity to disclose all events or information with respect to subsidiaries which are material for the listed entity, we wish to inform you that we have been informed that the Board of Directors of our material wholly-owned subsidiary, Jubilant Pharma Limited (“JPL”) has, at its meeting held on September 23, 2016, approved the proposal to launch a benchmark offering of unsecured high yield bonds (the “Notes”) outside India by JPL, under Regulation S of the US Securities Act. The Notes are proposed to be listed on the Singapore Exchange Securities Trading Limited.

The above is for your information and records.

Thanking You,

Yours Sincerely,
For Jubilant Life Sciences Limited


Rajiv Shah
Company Secretary



A Jubilant Bhartia Company

OUR VALUES



Jubilant Life Sciences Limited
1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubl.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223,
UP, India
CIN : L24116UP1978PLC004624